We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Distal Jejunal-release Dextrose in Obese Participants

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05385978
Recruitment Status : Recruiting
First Posted : May 23, 2022
Last Update Posted : January 12, 2023
Sponsor:
Information provided by (Responsible Party):
Aphaia Pharma US LLC

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The primary purpose of the study is to evaluate the efficacy and safety of APHD-012 (distal jejunal-release dextrose [Aphaia technology, AT]) in obese participants.

Condition or disease Intervention/treatment Phase
Obese Drug: APHD-012 Drug: APHD-012P Phase 2

Detailed Description:

This is a randomized, double-blind, placebo-controlled, parallel-group, phase II proof-of-concept study to be conducted in 150 adult obese male and female participants who are 18 to 70 years of age with or without one or more endocrine and/or metabolic conditions. The study aims to evaluate the efficacy and safety of distal jejunal-release dextrose (Aphaia technology, AT) in obese participants.

Participants will be randomly assigned to receive either APHD-012 (distal jejunal-release dextrose or APH-012P (a matching placebo). There will be two cohorts in the study. Participants from Cohort 1 will receive study medication once daily for 12 months (360 days), and participants from Cohort 2 will receive study medication once daily for 6 months (180 days).

Overall, 150 participants will be enrolled in the study:

  • Cohort 1 (60 participants) - 6-month treatment period + 6-month maintenance treatment period
  • Cohort 2 (90 participants) - 6-month treatment period
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 150 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Parallel Assignment Randomized, double-blind, placebo-controlled, parallel-group proof-of-concept efficacy and safety study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel-group Proof-of-concept Study to Evaluate Efficacy and Safety of Distal Jejunal-release Dextrose (Aphaia Technology, AT) in Obese Subjects
Actual Study Start Date : July 1, 2022
Estimated Primary Completion Date : March 30, 2024
Estimated Study Completion Date : March 30, 2024

Resource links provided by the National Library of Medicine

Drug Information available for: Dextrose

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Active Comparator: APHD-012
Participants will receive a single dose of APHD-012 12 g daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.
 Drug: APHD-012
Distal jejunal-release dextrose beads (Aphaia technology, AT)
Other Name: Distal jejunal-release dextrose beads
Placebo Comparator: APHD-012P
Participants will receive a single dose of APHD-012P daily, under fasting conditions prior to main daily meals for 180 days (6 months) for Cohort 2 and for 360 days (12 months) for Cohort 1.
 Drug: APHD-012P
Distal jejunal-release placebo beads
Other Name: Placebo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Changes from Baseline in Percent Weight Change Compared with Placebo [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]
    Bodyweight measurements will be done using standard personal balance referring to kilogram-Scale. Weighing will be done without shoes and with just underwear on. It is important that weighing is always done in the same way, preferably in the morning, before eating or drinking.


Secondary Outcome Measures :
  1. Percentage of Participants with ≥2.5% Baseline Body Weight Loss at 6 Months Compared with Placebo (Weight Loss Responders) [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]
    Body weight measurements will be done using standard personal balance referring to kilogram-Scale. Weighing will be done without shoes and with just underwear on. It is important that weighing is always done in the same way, preferably in the morning, before eating or drinking.

  2. Percentage of Participants with ≥5% Baseline Body Weight Loss at 6 Months Compared with Placebo (Weight Loss Responders) [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]
    Body weight measurements will be done using standard personal balance referring to kilogram-Scale. Weighing will be done without shoes and with just underwear on. It is important that weighing is always done in the same way, preferably in the morning, before eating or drinking.

  3. The Difference in Mean Absolute Weight Loss Compared with Placebo at 6 Months [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]
    Body weight measurements will be done using standard personal balance referring to kilogram-Scale. Weighing will be done without shoes and with just underwear on. It is important that weighing is always done in the same way, preferably in the morning, before eating or drinking.

  4. Mean Absolute Change and Percent Change of Waist Circumference [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]
    Waist circumference measurements will be done using a standard measuring tape referring to centimeter Scale.

  5. Mean Absolute Change and Percent Change of Systolic Blood Pressure and Diastolic Blood Pressure [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]
    Systolic blood pressure (SBP) and diastolic blood pressure (DBP) will be measured using a standard sphygmomanometer with the Riva-Rocci cuff and a stethoscope; alternatively, an automatic device with upper arm cuff can be used. Measurements are done in sitting position after 5 minutes of rest.

  6. Mean Absolute Change and Percent Change of Heart Rate [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]
    Heart rate measurement will be obtained along with the blood pressure measurement.

  7. Mean Absolute Change and Percent Change of Triglycerides and Cholesterol [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]
    Triglycerides and cholesterol (including total cholesterol, low-density lipoprotein [LDL], and high-density lipoprotein [HDL]) will be measured using standard clinical laboratory methods at the site laboratories.

  8. Mean Absolute Change and Percent Change of Homeostatic Model Assessment of Insulin Resistance [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]
    Homeostasis model assessment-estimated insulin resistance (HOMA-IR) will be determined with standard clinical laboratory methods.

  9. Mean Absolute Change and Percent Change of Fasting Plasma Glucose, Fasting Plasma Insulin and Glycated Hemoglobin [ Time Frame: At Baseline and at each visit until Day 180 for Cohort 2 and Day 360 for Cohort 1 ]

    Fasting plasma glucose will be determined using a standard blood glucometer. Fasting plasma insulin will be determined with standard clinical laboratory methods. Glycated hemoglobin (HbA1c) will be measured using a standard enzyme-linked immunoassay (ELISA) method.

    HbA1c will be measured in participants with type two diabetes (T2DM).


  10. Mean Absolute Change and Percent Change of Alanine Transaminase, Aspartate Transaminase and Gamma Glutamyl Transpeptidase [ Time Frame: At Baseline and at Day 90, at Day 180 for Cohort 2 and at Day 360 for Cohort 1 ]
    Liver enzymes (ALT, AST, GGT) will be measured using standard clinical laboratory methods.

  11. Mean Absolute Change and Percent Change of Fatty Liver Controlled Attenuation Parameter Score and Liver Fibrosis Score [ Time Frame: At Baseline and at Day 90, at Day 180 for Cohort 2 and at Day 360 for Cohort 1 ]

    Fatty liver Controlled Attenuation Parameter (CAP) Score will be measured in:

    • Participants with Non-alcoholic fatty liver disease (NAFLD): Steatosis grade and;
    • Participants with Non-alcoholic steatohepatitis (NASH): fibrosis Score category

    Fatty liver CAP Score and liver fibrosis Score will be measured using FibroScan™ equipment or equivalent.


  12. Number of Participants Reported with At least One Treatment Emergent Adverse Event (TEAE) [ Time Frame: At each visit until Day 180 for Cohort 2 and until Day 360 for Cohort 1 ]
    A treatment-emergent adverse event is defined as any event not present prior to the initiation of the drug treatment or any event already present that worsens in either intensity or frequency following exposure to the drug treatment

  13. Advance Understanding of Dose/Exposure - Response Relationships [ Time Frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1 ]
    Dose/Exposure - Response Relationships will be evaluated.


Other Outcome Measures:
  1. Glucagon-like Peptide-1 Level Determination [ Time Frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1 ]

    Blood samples of 2 mL will be taken at pre-dose (-0.5 h [within 5 minutes]) and 1.0, 2.0, 3.0, 4.0, 5.0, 6.0 and 8.0 hours after investigational medicinal product administration.

    The blood samples for the determination of Glucagon-like peptide-1 (GLP-1) and circulating biomarkers and micro Ribonucleic acid (miRNA)1983 will be collected in BD P800 tubes.


  2. Area Under the Plasma Concentration-time Curve from Time 0 to 8 Hours (AUC0-8) [ Time Frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1 ]
  3. Maximum Plasma Concentration (Cmax) [ Time Frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1 ]
  4. Time to Reach the Maximum Plasma Concentration (Tmax) [ Time Frame: At Baseline, at Day 90, Day 180 and at Day 360 for Cohort 1 ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Body mass index 30.0-39.9 kg/m^2 and/or waist circumference: men >102 cm, women >88 cm
  • Stable body weight: gain or loss in body weight ≤5 kg over last 3 months

  • Obese participants with or without one or more of the following conditions:

    1. NAFLD - simple steatosis based on a FibroScan CAP™ test result at screening (CAP Score ≥238 decibel-milliwatts (dB/m) (Steatosis Grades 1-3) with no or mild fibrosis (F0-F1 fibrosis Score)
    2. NASH - steatohepatitis based on FibroScan fibrosis Score at screening (≥7.5 kPa and <14 kPa (Stage F2-F3)
    3. Confirmed medical history of metabolic syndrome
    4. Homeostatic Model Assessment of Insulin Resistance (HOMA IR) Score ≥2
    5. Confirmed medical history of type 2 diabetes mellitus (T2DM) diagnosis or HbA1c ≥7.0 and <11 (based on screening values)
    6. High total cholesterol ≥240 mg/dL (based on screening values)
    7. Hypertension (participants with Stage 1 hypertension (systolic blood pressure [SBP] ≥130 mmHg <180 mmHg, diastolic blood pressure [DBP] ≥80 mmHg <110 mmHg) (based on screening values)

  • If on medication to manage endocrine/metabolic conditions, must be on stable doses of medication ≥3 months prior to screening:

    1. Participants with T2DM may be treated with either diet and exercise alone, metformin, sulphonylurea, thiazolidinediones, sodium-glucose cotransporter-2 (SGLT-2) inhibitors, and bromocriptine quick-release (QR) as single agents or combination therapy.
    2. As lipid-lowering medication participants may be treated with statins and fibrates, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, ezetimibe, or supplements like omega-3-fatty acids.
    3. As antihypertensive medication participants may be treated with beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II-inhibitors, diuretics, or calcium channel blockers.
  • Normal GI function, or abnormalities which the clinical investigator does not consider a disqualification for participation in the study

Exclusion Criteria:

  • Incomplete Coronavirus Disease of 2019 (COVID-19) vaccination
  • Treatment with weight loss medications in the past 3 months
  • Proven history of bulimia or anorexia nervosa
  • Treatment with injectable antidiabetic medications in the last 3 months (e.g. Glucagon-like peptide-1 [GLP-1] receptor agonists, insulin)
  • Treatment with dipeptidyl peptidase-4 inhibitors in the last 3 months
  • NASH with cirrhosis (fibrosis Score=F4 (≥14 kPa) as determined by screening FibroScan
  • Confirmed medical history of liver cirrhosis, cholestatic disease, alcohol-related liver disease
  • Type 1 diabetes mellitus, HbA1c ≥11, fasting plasma glucose levels ≥270 mg/dL
  • Proliferative retinopathy or maculopathy

  • Abnormal liver function tests:

    1. Transaminases:

      • Alanine transaminase (ALT)/aspartate aminotransferase (AST) ≥5 x upper limit of normal (ULN) for participants with NAFLD or NASH (as determined by screening FibroScan)
      • ALT/AST ≥2.5 x ULN for participants without NAFLD or NASH (as determined by screening FibroScan)
    2. Alkaline phosphatase (ALK) ≥2.5 x ULN
    3. Total bilirubin ≥2 x ULN
  • Stage 4 hypertension (SBP ≥180, DBP ≥110)
  • History or presence of any uncontrolled cardiovascular, pulmonary, hepatobiliary, renal, hematologic, gastrointestinal, endocrinologic, immunologic, dermatologic, neurological, psychiatric, metabolic, musculoskeletal, or malignant disease (except conditions accepted for inclusion) which the clinical investigator does not consider a disqualification for participation in the study
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05385978


Contacts
Layout table for location contacts
Contact: Kai Deusch, MD +41 41 784 96 33 deusch@aphaiapharma.com
Contact: Abbie Liu, MSc 787-299-6563 liu@aphaiapharma.com

Locations
Layout table for location information
Germany
Universitätsklinikum Schleswig-Holstein Recruiting
Lübeck, Germany, 23538
Contact: Franziska Klingbiel       franziska.klingbiel@uksh.de   
Universitätsklinikum Ruppin-Brandenburg Recruiting
Neuruppin, Germany, 16816
Contact: Silke Görgens       s.goergens@ruppiner-kliniken.de   
Puerto Rico
FDI Clinical Research Recruiting
San Juan, Puerto Rico
Contact: Michelle Echeandia       mecheandia@fdipr.com   
Sponsors and Collaborators
Aphaia Pharma US LLC
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Aphaia Pharma US LLC
ClinicalTrials.gov Identifier: NCT05385978    
Other Study ID Numbers: 034B20
First Posted: May 23, 2022    Key Record Dates
Last Update Posted: January 12, 2023
Last Verified: January 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Aphaia Pharma US LLC:
Obese
Dextrose
Hypertension
NASH
034B20
 Distal jejunal-release dextrose
Endocrine disorders
Metabolic conditions
NAFLD
Additional relevant MeSH terms:
Layout table for MeSH terms
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight